author-photo

Davide Pastorelli

University of Padua

37

Papers

961

Citations

Citation Trend

Filter By

Papers (27) Sort By

Journal Conference Others

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (197)
Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (6)
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study (vol 81, pg 17, 2017)

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
R1The effect of loneliness on cancer mortality

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma

2017 World Journal of Gastroenterology
Show All
- Source
- Cite
- Save
Citations (10)
The effect of loneliness on cancer mortality.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

2016 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (2)
Outcome of pancreaticoduodenectomy in octogenarians: Single institution's experience and review of the literature

2015 Journal of Visceral Surgery
Show All
- Source
- Cite
- Save
Citations (35)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (485)
O-005Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)